Misun Park 1 , Won Kyu Kim , Meiying Song , Minhee Park , Hyunki Kim , Hye Jin Nam , Sung Hee Baek , Hoguen Kim . Show Affiliations »
Abstract
PURPOSE: Abnormal signaling through receptor tyrosine kinase (RTK) moieties is important in tumorigenesis and drug targeting of colorectal cancers. Wild-type KIT (WT-KIT), a RTK that is activated upon binding with stem cell factor (SCF), is highly expressed in some colon cancers; however, little is known about the functional role of SCF-dependent KIT activation in colon cancer pathogenesis. We aimed to elucidate the conditions and roles of WT-KIT activation in colon cancer tumorigenesis. EXPERIMENTAL DESIGN: Colorectal cancers with KIT expression were characterized by immunoblotting and immunohistochemistry. The biologic alterations after KIT-SCF binding were analyzed with or without protein kinase C (PKC) activation. RESULTS: We found that WT-KIT was expressed in a subset of colon cancer cell lines and was activated by SCF, leading to activation of downstream AKT and extracellular signal-regulated kinase (ERK) signaling pathways. We also showed that KIT expression gradually decreased, after prolonged SCF stimulation, due to lysosomal degradation. Degradation of WT-KIT after SCF binding was significantly rescued when PKC was activated. We also showed the involvement of activated PKC-δ in the recycling of WT-KIT. We further showed that a subset of colorectal cancers exhibit expressions of both WT-KIT and activated PKC-δ and that expression of KIT is correlated with poor patient survival (P = 0.004). CONCLUSIONS: Continuous downstream signal activation after KIT-SCF binding is accomplished through PKC-δ-mediated recycling of KIT. This sustained KIT activation may contribute to tumor progression in a subset of colon cancers with KIT expression and might provide the rationale for a therapeutic approach targeting KIT. ©2013 AACR.
PURPOSE: Abnormal signaling through receptor tyrosine kinase (RTK) moieties is important in tumorigenesis and drug targeting of colorectal cancers . Wild-type KIT (WT-KIT ), a RTK that is activated upon binding with stem cell factor (SCF), is highly expressed in some colon cancers ; however, little is known about the functional role of SCF-dependent KIT activation in colon cancer pathogenesis. We aimed to elucidate the conditions and roles of WT-KIT activation in colon cancer tumorigenesis. EXPERIMENTAL DESIGN: Colorectal cancers with KIT expression were characterized by immunoblotting and immunohistochemistry. The biologic alterations after KIT -SCF binding were analyzed with or without protein kinase C (PKC ) activation. RESULTS: We found that WT-KIT was expressed in a subset of colon cancer cell lines and was activated by SCF, leading to activation of downstream AKT and extracellular signal-regulated kinase (ERK) signaling pathways. We also showed that KIT expression gradually decreased, after prolonged SCF stimulation, due to lysosomal degradation. Degradation of WT-KIT after SCF binding was significantly rescued when PKC was activated. We also showed the involvement of activated PKC -δ in the recycling of WT-KIT . We further showed that a subset of colorectal cancers exhibit expressions of both WT-KIT and activated PKC -δ and that expression of KIT is correlated with poor patient survival (P = 0.004). CONCLUSIONS: Continuous downstream signal activation after KIT -SCF binding is accomplished through PKC -δ-mediated recycling of KIT . This sustained KIT activation may contribute to tumor progression in a subset of colon cancers with KIT expression and might provide the rationale for a therapeutic approach targeting KIT . ©2013 AACR.
Entities: Disease
Gene
Species
Mesh: See more »
Substances: See more »
Year: 2013
PMID: 23881925 DOI: 10.1158/1078-0432.CCR-13-0131
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531